Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) took a rather sharp beating yesterday on word that it was going to have a secondary offering. We now have details on that offering and it comes to 7.5 million shares at a price of $10.75 per share. Keep in mind that he $10.98 close on Tuesday was down from $12.39 on Monday and the close last Thursday was $13.05.
The company has a broad and diverse pipeline with many key partners. All of the shares are being sold by Alnylam.
The underwriting group is larger than what we originally saw as well: J.P. Morgan Securities is acting as the sole book-running manager for the offering; co-managers were listed as Leerink Swann, Needham & Company, JMP Securities, Rodman & Renshaw, MLV & Co., and Chardan Capital Markets. These underwriters have an overallotment option of 1.125 million shares.
Alnylam shares are trading up marginally at $11.00 per share as the appearance of the worst seems to be over. This one took a pretty steep haircut even before the secondary was announced and this will allow it to further develop that extensive pipeline and partnerships.
JON C. OGG
Sponsored: Want to Retire Early? Here’s a Great First Step
Want retirement to come a few years earlier than you’d planned? Orare you ready to retire now, but want an extra set of eyes on your finances?
Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Editors' Picks
